ADC Therapeutics S.A.
ADC Therapeutics S.A. (ADCT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ADCT · as of Jun 8, 2026
Key Statistics
Explore ADC Therapeutics S.A. Data
adct stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 50.0%
The ADCT analyst consensus is Buy, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $3.50, representing +239.81% upside from the current price of $1.03.
Competitors & Peers
adct competitorsADCT
ALMS
AUTL
BCYC
FDMT
LCTXStock Performance
Full HistoryAbout ADC Therapeutics S.A.
ADC Therapeutics S.A. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYN…
what is adc therapeutics s.a. · adct stock overview · adc therapeutics s.a. company profile · who is adc therapeutics s.a. ceo · adct NYSE · adc therapeutics s.a. headquarters · adc therapeutics s.a. business segments
About Stock Overview & Key Data
ADC Therapeutics S.A. (ADCT) is a Healthcare company in the Biotechnology industry, listed on NYSE since May 18, 2020. As of the latest trading session, ADCT stock price is $1.03, with a market capitalization of $131.0M. The stock has returned -71.15% over the past 12 months and -70.82% year-to-date.
According to 12 Wall Street analysts, the consensus rating for ADC Therapeutics S.A. stock is Buy, with an average 12-month price target of $3.50. In fiscal year 2025, ADC Therapeutics S.A. reported revenue of $81.4M and net income of -$142.6M. For detailed data — including ADC Therapeutics S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ADC Therapeutics S.A. (ADCT) stock price is $1.03. The stock is traded on NYSE under the ticker symbol ADCT. The 52-week range is $1.02 – $4.98.